PE-22-28 vs Teduglutide
Side-by-side comparison of key properties, dosing, and research.
Cognitive Enhancement
PE-22-28Recovery & Repair
Teduglutide- Summary
- PE-22-28 is a synthetic analog of spadin derived from sortilin, designed to block TREK-1 potassium channels with rapid-onset antidepressant and neurogenic effects. It shows fast-acting depression relief (within 24 hours) and promotes hippocampal neurogenesis.
- Teduglutide is a GLP-2 (glucagon-like peptide-2) analog with enhanced stability. Unlike GLP-1, GLP-2 specifically acts on the intestinal epithelium to increase intestinal length, villus height, and absorption surface area. FDA-approved as Gattex for short bowel syndrome, it is also being investigated for IBD, leaky gut, and mucosal healing.
- Half-Life
- Relatively short; CNS effects may persist due to neurogenic mechanisms
- ~2 hours; once-daily dosing due to gut-specific residence
- Admin Route
- SubQ, Intranasal
- SubQ
- Research
- —
- —
- Typical Dose
- 200–400 mcg
- 0.05 mg/kg/day
- Frequency
- Once daily
- Once daily
- Key Benefits
- Rapid-onset antidepressant effects (within 24 hours)
- Promotes hippocampal neurogenesis
- Improves cognitive performance and memory
- Reduces anxiety and depressive behavior
- Novel mechanism — does not act on serotonin/dopamine/GABA receptors directly
- May help treatment-resistant depression
- Neuroprotective effects
- Increases intestinal villus height and absorption surface area
- Reduces intestinal permeability (leaky gut)
- FDA-approved for short bowel syndrome
- Reduces parenteral nutrition dependence in SBS patients
- Promotes intestinal mucosal healing in IBD
- Increases tight junction proteins ZO-1 and occludin
- Side Effects
- Generally well tolerated in animal models
- Limited human data available
- Possible mild headache or transient mood changes at initiation
- Injection site reactions (SC)
- Injection site reactions
- Abdominal pain and bloating
- Nausea
- Risk of intestinal polyp growth (requires colonoscopy surveillance)
- +1 more
- Stacks With
- —
- —